CTLA4 and cancer: Notably, high Nrf2 expression was also correlated with worse survival outcomes in cancer patients undergoing immune checkpoint inhibitor therapies, including anti‐PD1 and anti‐CTLA‐4 treatments, irrespective of cancer types (Figure 2A, middle).